Anti-Claudin-1 Conjugated to a Near-Infrared Fluorophore Targets Colon Cancer in PDOX Mouse Models.

INTRODUCTION Claudins are tight-junction proteins, which maintain an epithelial barrier in normal colon cells. Overexpression of Claudin-1 has been implicated for development of colon cancer. We postulated that Claudin-1 may be a useful target in near-infrared imaging and fluorescence-guided surgery. METHODS We conjugated Claudin-1 antibody to LI-COR IR800DyeCW (Claudin-1-IRDye800CW). Western blotting of 9 human colon cancer cell lysates was performed. Animal imaging was performed with the LI-COR Pearl Trilogy Fluorescence Imaging System. A dose-response study was carried out with subcutaneous LS174T colon cancer cell line models. Increasing doses of Claudin-1-IRDye800CW via tail vein injection were administered to three groups of mice. Two groups of mice were used as controls (antibody alone, and dye alone). In vivo imaging was performed at 24, 48, and 72 h after administration of the conjugated dye. Orthotopic implantation of patient-derived tumors and cell lines was performed and peritoneal carcinomatosis models were created. After tumor growth, mice were administered Claudin-1-IRDye800CW and imaged in vivo 48 h later. The mice were euthanized and laparotomy was performed to assess internal organs and toxicity. RESULTS Western blotting revealed that all colon cancer cell lysates expressed varying amounts of Claudin-1. All tumors demonstrated strong and specific fluorescence labeling at 800 nm, even with the lowest dose of 12.5 μg of Claudin-1-IRDye800CW. CONCLUSIONS Claudin-1 is a useful target for near-infrared antibody-based imaging for visualization of colorectal tumors for future use in fluorescence-guided surgery.

[1]  R. Hoffman Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts , 2015, Nature Reviews Cancer.

[2]  Thinzar M. Lwin,et al.  Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model , 2018, BiOS.

[3]  N. S. van den Berg,et al.  The Clinical Application of Fluorescence-Guided Surgery in Head and Neck Cancer , 2019, The Journal of Nuclear Medicine.

[4]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[5]  P. Dhawan,et al.  Claudin proteins, outside-in signaling, and carcinogenesis , 2016, Pflügers Archiv - European Journal of Physiology.

[6]  M. Washington,et al.  Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenamatous polyposis coli-mediated colon tumorigenesis , 2014, Molecular Cancer.

[7]  Thomas D. Wang,et al.  Overexpressed Claudin-1 Can Be Visualized Endoscopically in Colonic Adenomas In Vivo , 2015, Cellular and molecular gastroenterology and hepatology.

[8]  X. Chen,et al.  Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. , 2011, Gastroenterology.

[9]  Yukihiko Hiroshima,et al.  Near Infra-Red Photoimmunotherapy with Anti-CEA-IR700 Results in Extensive Tumor Lysis and a Significant Decrease in Tumor Burden in Orthotopic Mouse Models of Pancreatic Cancer , 2015, PloS one.

[10]  Alexander L Vahrmeijer,et al.  Oncologic Procedures Amenable to Fluorescence-guided Surgery , 2017, Annals of surgery.

[11]  M. Washington,et al.  Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. , 2005, The Journal of clinical investigation.

[12]  M. Washington,et al.  Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling , 2013, Gut.

[13]  Yukihiko Hiroshima,et al.  Photoimmunotherapy Inhibits Tumor Recurrence After Surgical Resection on a Pancreatic Cancer Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model , 2015, Annals of Surgical Oncology.

[14]  Leonora S F Boogerd,et al.  Safety and effectiveness of SGM-101, a fluorescent antibody targeting carcinoembryonic antigen, for intraoperative detection of colorectal cancer: a dose-escalation pilot study. , 2018, The lancet. Gastroenterology & hepatology.

[15]  Anne Wallace,et al.  Positive Surgical Margins in the 10 Most Common Solid Cancers , 2018, Scientific Reports.